Clinical Trials

80 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07226180 2026-03-18

Development and Application of Patient-Derived Models of Cancer

Enrolling by invitation

40 enrolled

Neoplasms

NCT07424547 2026-03-18

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

BreastGenitourinaryGynecologicThoracic

386 enrolled

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07479381 2026-03-18

CLEAR

Not yet recruiting

1,450 enrolled

Gastrointestinal

Disease, Neoplasms, Colorectal Neoplasms

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

284 enrolled

MyeloidOther hematologic neoplasm

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT02467270 2026-03-17

OPTIC

Phase 2 Completed

283 enrolled 31 charts

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04486378 2026-03-17

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 1 Active not recruiting

327 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

151 enrolled

Neoplasms

NCT06993844 2026-03-17

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

BreastGynecologicHead & Neck

233 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

134 enrolled

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07342517 2026-03-17

RESCUE

Phase 3 Withdrawn

Phase 1 Not yet recruiting

Neoplasms, Urologic Neoplasms

NCT07476326 2026-03-17

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

120 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT04928846 2026-03-16

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

698 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06150157 2026-03-16

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

220 enrolled

Neoplasms

NCT06997029 2026-03-16

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

234 enrolled

Neoplasms

NCT07002034 2026-03-16

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

100 enrolled

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

NCT07030712 2026-03-16

MK-8294-001

67 enrolled

Neoplasm Metastasis, Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07252739 2026-03-16

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT07387471 2026-03-16

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

14 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT02808780 2026-03-13

OPAL

Active not recruiting

537 enrolled

Lymphoid

Colitis, Ulcerative, Lymphoma, Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05862285 2026-03-13

UmbrellaMAX

100 enrolled

Neoplasms

NCT06178614 2026-03-13

A Study of JNJ-87890387 for Advanced Solid Tumors

200 enrolled

Neoplasms

NCT06941272 2026-03-13

MK-9999-01C

50 enrolled

Neoplasms

NCT07023289 2026-03-13

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Phase 1 Not yet recruiting

140 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07462468 2026-03-13

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

36 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT02908906 2026-03-12

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

413 enrolled

Phase NA Active not recruiting

Neoplasms

NCT04618913 2026-03-12

VICTORIE

Active not recruiting

1 enrolled

Classical hematology

Embolism, Neoplasms, Venous Thromboembolism

NCT04905069 2026-03-12

SABRE

500 enrolled

Neoplasms, Prostatic Neoplasms

NCT06119581 2026-03-12

SUNRAY-01

1,264 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07100730 2026-03-12

IPAX BrIGHT

Phase NA Not yet recruiting

50 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

NCT07465796 2026-03-12

CIPHER

10 enrolled

CNS

Glioma, Neoplasms

NCT05993299 2026-03-11

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06088290 2026-03-11

SaLuDo

450 enrolled

Sarcoma

Leiomyosarcoma, Neoplasms

NCT06901531 2026-03-11

LUCERNA

500 enrolled

Adenocarcinoma, Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Recruiting

377 enrolled

Adenocarcinoma, Neoplasms

NCT07046260 2026-03-11

PROCARES

Recruiting

1,650 enrolled

Disease, Neoplasms

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

430 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07464145 2026-03-11

RESCUE

393 enrolled

BreastGastrointestinalGynecologicThoracic

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

616 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06533059 2026-03-09

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors